Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Spotlight: Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

Sharmilee Nuli, Rajshekhar Chakraborty, Al-Ola Abdallah, Suzanne Lentzsch, Evguenia Ouchveridze, Douglas W Sborov, Amandeep Godara, Brian McClune, Ah-Reum Jeong, Samuel M. Rubinstein, Aaron Goodman, Ghulam Rehman Mohyuddin

Blood (2024) 144 (Supplement 1): 6924.

https://doi.org/10.1182/blood-2024-203731

Published: 2024

Journal Articles

ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma

Ghulam Rehman Mohyuddin, Amandeep Godara, Brian McClune, Gliceida Galarza Fortuna, Karen Sweiss, Matias Sanchez, Hira Mian, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 6916.

https://doi.org/10.1182/blood-2024-208861

Published: 2024

Journal Articles

Cardiovascular Events in Multiple Myeloma: A Retrospective Review of the SEER-Medicare Claims Database

Victoria A. Vardell, Joshua J. Horns, Anees A Daud, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 6942.

https://doi.org/10.1182/blood-2024-210695

Published: 2024

Journal Articles

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Blood (2024) 144 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2024-198499

Published: 2024

Journal Articles

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 931.

https://doi.org/10.1182/blood-2024-202017

Published: 2024

Journal Articles

Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups

Blood (2024) 144 (Supplement 1): 675.

https://doi.org/10.1182/blood-2024-201736

Published: 2024

Journal Articles

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Blood (2024) 144 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2024-204257

Published: 2024

Journal Articles

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Blood (2024) 144 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2024-205614

Published: 2024

Journal Articles

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Matthew Pianko, Charlotte Pawlyn, Shang-Yi Huang, Tadao Ishida, Douglas W Sborov, Shinsuke Iida, Aravind Ramakrishnan, Reuben Benjamin, Rakesh Popat, Steven Schuster, Junya Kuroda, Chia-Jen Liu, Anne Philippe, Umberto Conte, Fangxin Hong, Erik Vandendries, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2024-205872

Published: 2024

Journal Articles

National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma

Karen Sweiss, Jay R. Hydren, Jorge Arturo Hurtado Martinez, Mason S. Barnes, Pritesh Patel, Douglas W Sborov, Jennifer M. Ahlstrom, Lisa Sharp, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 283.

https://doi.org/10.1182/blood-2024-210314

Published: 2024

Journal Articles

First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Karen Sweiss, Jay R. Hydren, Jorge Arturo Hurtado Martinez, Mason S. Barnes, Pritesh Patel, Douglas W. Sborov, Jennifer M. Ahlstrom, Lisa Sharp, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 5144.

https://doi.org/10.1182/blood-2024-210437

Published: 2024

Journal Articles

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 897.

https://doi.org/10.1182/blood-2024-203409

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 934.

https://doi.org/10.1182/blood-2024-205989

Published: 2024

Journal Articles

Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study

Blood (2024) 144 (Supplement 1): 3760.

https://doi.org/10.1182/blood-2024-201712

Published: 2024

Journal Articles

Venetoclax in Patients with Multiple Myeloma with or without t(11;14): A Real-World Analysis

Edward R Scheffer Cliff, Martin F Kaiser, Douglas W. Sborov, Rafael Fonseca, Ghulam Rehman Mohyuddin

Blood (2024) 144 (Supplement 1): 3792.6.

https://doi.org/10.1182/blood-2024-207365

Published: 2024

Journal Articles

Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting

Craig C. Hofmeister, Mingyuan Zhang, Vikas A. Gupta, Nisha S. Joseph, Jonathan L. Kaufman, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial, Douglas W. Sborov

Blood (2024) 144 (Supplement 1): 5152.

https://doi.org/10.1182/blood-2024-202100

Published: 2024

Journal Articles

Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey

Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Katherine Berger, Ryan Winborg, Mason S. Barnes, Jorge Arturo Hurtado Martinez, Jay R. Hydren, Douglas W Sborov, Amandeep Godara, Brian McClune, Christopher Booth, Edward R Scheffer Cliff

Blood (2024) 144 (Supplement 1): 2281.

https://doi.org/10.1182/blood-2024-208803

Published: 2024

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Michel Delforge, Joshua Richter, Yael C. Cohen, Paolo Corradini, Douglas W Sborov, Alexander M. Lesokhin, Jesus G Berdeja, Moshe E Gatt, Laura Paris, Laura Rosinol Dachs, Hang Quach, Manisha Kanwar, Olivier Catalani, Paresh Sewpaul, Elisabeth Wassner-Fritsch, Ameet Mishra, Kerstin Trunzer, Shaji Kumar

Blood (2024) 144 (Supplement 1): 4732.

https://doi.org/10.1182/blood-2024-199519

Published: 2024

NARROW

Spotlight: Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

ULTRA FRAIL-MM Clinical Trial: Go-Slow Approach Incorporating Isatuximab, Lenalidomide and Dexamethasone for Ultra-Frail Newly Diagnosed Myeloma

Cardiovascular Events in Multiple Myeloma: A Retrospective Review of the SEER-Medicare Claims Database

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups

Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma

First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study

Venetoclax in Patients with Multiple Myeloma with or without t(11;14): A Real-World Analysis

Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting

Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only